Generic name: itraconazole
Used for: Fungal nail infections · Blastomycosis (a fungal infection) · Histoplasmosis (a fungal infection) · Aspergillosis (a fungal infection) · 3 more
Lowest price anyone can pay
$22.05 for 30 capsules delivered ($16.80 plus $5.25 shipping)
Generic itraconazole 100 mg from Cost Plus Drugs, by mail
Need it today? $24.22 for 30 capsules with the free Team Cuban Card, at pharmacies that take it. Get the free card and show it there.
See the price and get the cardA regular generic has the same active ingredient as Sporanox, and the FDA requires it to work the same way.
Details for each option
We didn’t find a savings card or cash price from Sporanox’s maker. Ask the pharmacy for Sporanox’s cash price. With insurance, ask what your plan charges.
The same medicine as Sporanox, without the brand name. Give the pharmacy its NDC to get it.
itraconazole
Source: FDA, updated October 30, 2026
“Before you fill my Sporanox, can you tell me what I’d pay for the brand, for the authorized generic from Patriot Pharmaceuticals (NDC 10147-1700-3), and for a regular generic?”
Paying cash? Ask for each one’s cash price. With insurance, ask what your plan charges for each.
Official labels and ingredient lists from DailyMed (U.S. National Library of Medicine).
Same active and inactive ingredients as Sporanox.
Active: itraconazole 100 mg
Inactive, on both labels:
Pharmacies’ own cash prices for generic itraconazole, lowest first.
Pick up in storeDelivered
From each pharmacy’s own site, read November 2, 2026. Confirm the price before you fill.
Prices change, can differ by store and state, and may depend on the strength and how many you take. With insurance, ask what your plan charges; it can be less.
8 companies sell a generic of Sporanox that the FDA rates a substitute. A pharmacy fills whichever one it stocks. To get a certain maker, ask for it by name; most pharmacies can order it in a day or two.
Has dyes: D&C Red No. 22, D&C Red No. 28, FD&C Blue No. 1
100 mg Blue opaque pink transparent, capsule, 21 mm, marked “A / 175”
| Package | NDC |
|---|---|
| Carton of 28 | 62332-204-04 |
| Bottle of 30 | 62332-204-30 |
| Bottle of 90 | 62332-204-90 |
| Carton of 100 | 62332-204-10 |
| Bottle of 500 | 62332-204-71 |
Inactive ingredients: sucrose, hypromellose, polyethylene glycol 20000, titanium dioxide, D&C Red No. 22, FD&C Blue No. 1, D&C Red No. 28, gelatin, starch, corn, shellac, ferrosoferric oxide, potassium hydroxide
Has a dye: FD&C Blue No. 1
10 mg/mL Clear-yellowish
| Package | NDC |
|---|---|
| Tray of 100 mL | 65162-087-34 |
| Bottle of 150 mL | 65162-087-74 |
100 mg Transparent and opaque, capsule, 22 mm, marked “AMNEAL / 630”
| Package | NDC |
|---|---|
| Bottle of 30 | 65162-630-03 |
Inactive ingredients: hydrochloric acid, propylene glycol, water, sodium hydroxide, saccharin sodium, sorbitol, ferrosoferric oxide, FD&C Blue No. 1, gelatin, hypromelloses, cellulose, microcrystalline, polyethylene glycol, potassium hydroxide, shellac, sodium lauryl sulfate, starch, corn, ammonia, sucrose, titanium dioxide, dextrose
Has dyes: FD&C Blue No. 1, FD&C Red No. 3, FD&C Red No. 40 · Made by Alkem Laboratories
100 mg Blue Opaque and Pink transparent, capsule, 21 mm, marked “ITR / 100”
| Package | NDC |
|---|---|
| Bottle of 30 | 67877-454-30 |
| Carton of 30 | 67877-454-84 |
| Bottle of 90 | 67877-454-90 |
| Bottle of 500 | 67877-454-05 |
Inactive ingredients: sucrose, hypromellose 2910 (5 mpa.s), poloxamer 188, alcohol, methylene chloride, polyethylene glycol 20000, talc, silicon dioxide, gelatin, titanium dioxide, sodium lauryl sulfate, FD&C Blue No. 1, FD&C Red No. 40, FD&C Red No. 3, shellac, isopropyl alcohol, butyl alcohol, propylene glycol, ammonia, potassium hydroxide, starch, corn
Made by Annora Pharma
Product page on camberpharma.com
10 mg/mL Colorless to yellowish brown
| Package | NDC |
|---|---|
| Carton of 150 mL | 31722-006-31 |
Inactive ingredients: ascorbic acid, hydrochloric acid, propylene glycol, water, noncrystallizing sorbitol solution, saccharin sodium, sodium hydroxide
Made by Annora Pharma
10 mg/mL
| Package | NDC |
|---|---|
| Box of 400 mL | 69339-159-17 |
Inactive ingredients: ascorbic acid, hydrochloric acid, propylene glycol, water, noncrystallizing sorbitol solution, saccharin sodium, sodium hydroxide
Has dyes: FD&C Blue No. 1, FD&C Red No. 3, FD&C Red No. 40 · Made by Alkem Laboratories
Product page on northstarrxllc.com
100 mg Blue Opaque and Pink transparent, capsule, 21 mm, marked “ITR / 100”
| Package | NDC |
|---|---|
| Carton of 28 | 16714-743-01 |
| Bottle of 30 | 16714-743-02 |
Inactive ingredients: sucrose, hypromellose 2910 (5 mpa.s), poloxamer 188, alcohol, methylene chloride, polyethylene glycol 20000, talc, silicon dioxide, gelatin, titanium dioxide, sodium lauryl sulfate, FD&C Blue No. 1, FD&C Red No. 40, FD&C Red No. 3, shellac, isopropyl alcohol, butyl alcohol, propylene glycol, ammonia, potassium hydroxide, starch, corn
100 mg White, capsule, 23 mm, marked “ITR / 100”
| Package | NDC |
|---|---|
| Bottle of 30 | 16571-245-03 |
Inactive ingredients: gelatin, hypromellose 2910 (5 mpa.s), polyethylene glycol 20000, sucrose, starch, corn, titanium dioxide, ferrosoferric oxide, potassium hydroxide, propylene glycol, shellac, ammonia
Has dyes: D&C Red No. 28, FD&C Blue No. 1, FD&C Blue No. 2
100 mg Blue opaque cap and pink transparent body, capsule, 22 mm, marked “100 / 1463”
| Package | NDC |
|---|---|
| Carton of 28 | 13668-463-37 |
| Bottle of 30 | 13668-463-30 |
| Bottle of 90 | 13668-463-90 |
| Bottle of 500 | 13668-463-05 |
Inactive ingredients: D&C Red No. 28, FD&C Blue No. 1, FD&C Blue No. 2, ferrosoferric oxide, gelatin, hypromellose 2910 (5 mpa.s), polyethylene glycol 20000, potassium hydroxide, propylene glycol, shellac, starch, corn, sucrose, talc, titanium dioxide
Who sells it: FDA and Medicaid records, updated weekly. Each maker’s page, card and program is from its own site.
SPORANOX® (itraconazole) Capsules are indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients:
Specimens for fungal cultures and other relevant laboratory studies (wet mount, histopathology, serology) should be obtained before therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, antiinfective therapy should be adjusted accordingly.
SPORANOX® Capsules are also indicated for the treatment of the following fungal infections in non-immunocompromised patients:
Prior to initiating treatment, appropriate nail specimens for laboratory testing (KOH preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis of onychomycosis.
(See CLINICAL PHARMACOLOGY: Special Populations, CONTRAINDICATIONS, WARNINGS, and ADVERSE REACTIONS: Postmarketing Experience for more information.)
Description of Clinical Studies
Blastomycosis
Analyses were conducted on data from two open-label, non-concurrently controlled studies (N=73 combined) in patients with normal or abnormal immune status. The median dose was 200 mg/day. A response for most signs and symptoms was observed within the first 2 weeks, and all signs and symptoms cleared between 3 and 6 months. Results of these two studies demonstrated substantial evidence of the effectiveness of itraconazole for the treatment of blastomycosis compared with the natural history of untreated cases.
Histoplasmosis
Analyses were conducted on data from two open-label, non-concurrently controlled studies (N=34 combined) in patients with normal or abnormal immune status (not including HIV-infected patients). The median dose was 200 mg/day. A response for most signs and symptoms was observed within the first 2 weeks, and all signs and symptoms cleared between 3 and 12 months. Results of these two studies demonstrated substantial evidence of the effectiveness of itraconazole for the treatment of histoplasmosis, compared with the natural history of untreated cases.
Histoplasmosis in HIV-infected patients
Data from a small number of HIV-infected patients suggested that the response rate of histoplasmosis in HIV-infected patients is similar to that of non-HIV-infected patients. The clinical course of histoplasmosis in HIV-infected patients is more severe and usually requires maintenance therapy to prevent relapse.
Aspergillosis
Analyses were conducted on data from an open-label, "single-patient-use" protocol designed to make itraconazole available in the U.S. for patients who either failed or were intolerant of amphotericin B therapy (N=190). The findings were corroborated by two smaller open-label studies (N=31 combined) in the same patient population. Most adult patients were treated with a daily dose of 200 to 400 mg, with a median duration of 3 months. Results of these studies demonstrated substantial evidence of effectiveness of itraconazole as a second-line therapy for the treatment of aspergillosis compared with the natural history of the disease in patients who either failed or were intolerant of amphotericin B therapy.
Onychomycosis of the toenail
Analyses were conducted on data from three double-blind, placebo-controlled studies (N=214 total; 110 given SPORANOX® Capsules) in which patients with onychomycosis of the toenails received 200 mg of SPORANOX® Capsules once daily for 12 consecutive weeks. Results of these studies demonstrated mycologic cure, defined as simultaneous occurrence of negative KOH plus negative culture, in 54% of patients. Thirty-five percent (35%) of patients were considered an overall success (mycologic cure plus clear or minimal nail involvement with significantly decreased signs) and 14% of patients demonstrated mycologic cure plus clinical cure (clearance of all signs, with or without residual nail deformity). The mean time to overall success was approximately 10 months. Twenty-one percent (21%) of the overall success group had a relapse (worsening of the global score or conversion of KOH or culture from negative to positive).
Onychomycosis of the fingernail
Analyses were conducted on data from a double-blind, placebo-controlled study (N=73 total; 37 given SPORANOX® Capsules) in which patients with onychomycosis of the fingernails received a 1-week course (pulse) of 200 mg of SPORANOX® Capsules b.i.d., followed by a 3-week period without SPORANOX®, which was followed by a second 1-week pulse of 200 mg of SPORANOX® Capsules b.i.d. Results demonstrated mycologic cure in 61% of patients. Fifty-six percent (56%) of patients were considered an overall success and 47% of patients demonstrated mycologic cure plus clinical cure. The mean time to overall success was approximately 5 months. None of the patients who achieved overall success relapsed.
Source: the FDA label for Sporanox (Janssen Pharmaceuticals, Inc.), July 13, 2026. Full label on DailyMed
Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/sporanox/